Stem definition | Drug id | CAS RN |
---|---|---|
2272 | 671-16-9 |
None
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 27.11 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
July 22, 1969 | FDA | SIGMA TAU |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nausea | 145.39 | 29.61 | 190 | 2614 | 687264 | 45995994 |
Blood count abnormal | 102.44 | 29.61 | 39 | 2765 | 17839 | 46665419 |
Fatigue | 67.93 | 29.61 | 126 | 2678 | 608571 | 46074687 |
Maternal exposure before pregnancy | 66.50 | 29.61 | 20 | 2784 | 4461 | 46678797 |
Disease progression | 64.14 | 29.61 | 49 | 2755 | 91251 | 46592007 |
Neutropenia | 57.92 | 29.61 | 56 | 2748 | 143148 | 46540110 |
Hepatocellular injury | 51.16 | 29.61 | 28 | 2776 | 29494 | 46653764 |
Platelet count decreased | 47.89 | 29.61 | 43 | 2761 | 99981 | 46583277 |
Psychiatric decompensation | 45.13 | 29.61 | 11 | 2793 | 1112 | 46682146 |
Persecutory delusion | 40.49 | 29.61 | 12 | 2792 | 2543 | 46680715 |
Meningoencephalitis herpetic | 40.48 | 29.61 | 10 | 2794 | 1068 | 46682190 |
Necrotising gastritis | 40.38 | 29.61 | 6 | 2798 | 38 | 46683220 |
Febrile neutropenia | 40.07 | 29.61 | 38 | 2766 | 94589 | 46588669 |
Rectal adenoma | 37.77 | 29.61 | 6 | 2798 | 62 | 46683196 |
Malignant neoplasm progression | 37.30 | 29.61 | 31 | 2773 | 64895 | 46618363 |
Aplasia | 36.52 | 29.61 | 12 | 2792 | 3564 | 46679694 |
White blood cell count decreased | 36.39 | 29.61 | 39 | 2765 | 112192 | 46571066 |
Second primary malignancy | 36.36 | 29.61 | 14 | 2790 | 6570 | 46676688 |
Central nervous system lymphoma | 34.14 | 29.61 | 9 | 2795 | 1245 | 46682013 |
Thrombocytopenia | 32.55 | 29.61 | 39 | 2765 | 126542 | 46556716 |
Hepatitis B reactivation | 32.46 | 29.61 | 9 | 2795 | 1505 | 46681753 |
Constipation | 31.35 | 29.61 | 45 | 2759 | 174052 | 46509206 |
Myelodysplastic syndrome | 30.27 | 29.61 | 16 | 2788 | 15695 | 46667563 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute myeloid leukaemia | 211.63 | 31.27 | 81 | 3696 | 17925 | 29930776 |
Nausea | 169.28 | 31.27 | 196 | 3581 | 296761 | 29651940 |
Second primary malignancy | 157.79 | 31.27 | 50 | 3727 | 6306 | 29942395 |
Myelodysplastic syndrome | 123.90 | 31.27 | 56 | 3721 | 18722 | 29929979 |
Malignant transformation | 121.52 | 31.27 | 26 | 3751 | 687 | 29948014 |
Fatigue | 90.04 | 31.27 | 151 | 3626 | 320522 | 29628179 |
Blood count abnormal | 87.25 | 31.27 | 38 | 3739 | 11614 | 29937087 |
Blood stem cell transplant failure | 86.80 | 31.27 | 18 | 3759 | 407 | 29948294 |
Azoospermia | 81.12 | 31.27 | 17 | 3760 | 405 | 29948296 |
Neutropenia | 77.78 | 31.27 | 88 | 3689 | 128452 | 29820249 |
Hepatocellular injury | 59.26 | 31.27 | 38 | 3739 | 25433 | 29923268 |
Testicular disorder | 58.73 | 31.27 | 14 | 3763 | 606 | 29948095 |
Myositis | 50.13 | 31.27 | 25 | 3752 | 10352 | 29938349 |
Angiodysplasia | 46.44 | 31.27 | 11 | 3766 | 463 | 29948238 |
Transformation to acute myeloid leukaemia | 43.06 | 31.27 | 11 | 3766 | 635 | 29948066 |
Malignant neoplasm progression | 41.06 | 31.27 | 48 | 3729 | 72239 | 29876462 |
Premature ageing | 37.91 | 31.27 | 7 | 3770 | 84 | 29948617 |
Heart disease congenital | 35.80 | 31.27 | 11 | 3766 | 1247 | 29947454 |
Osteonecrosis | 34.87 | 31.27 | 23 | 3754 | 16112 | 29932589 |
Bone marrow failure | 34.12 | 31.27 | 29 | 3748 | 29756 | 29918945 |
Source | Code | Description |
---|---|---|
ATC | L01XB01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Methylhydrazines |
FDA MoA | N0000000236 | Alkylating Activity |
FDA EPC | N0000175558 | Alkylating Drug |
MeSH PA | D000970 | Antineoplastic Agents |
CHEBI has role | CHEBI:35610 | cytostatic |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hodgkin's disease | indication | 118599009 | |
Astrocytoma, anaplastic | off-label use | 55353007 | DOID:3078 |
Diffuse non-Hodgkin's lymphoma, large cell | off-label use | 109969005 | |
Polycythemia vera | off-label use | 109992005 | |
Mycosis fungoides | off-label use | 118618005 | |
Glioblastoma multiforme of brain | off-label use | 276828006 | DOID:3073 |
Malignant neoplasm of brain | off-label use | 428061005 | DOID:1319 |
Mycosis | contraindication | 3218000 | DOID:1564 |
Alcoholism | contraindication | 7200002 | |
Viral disease | contraindication | 34014006 | DOID:934 |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Bacterial infectious disease | contraindication | 87628006 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Peripheral nerve disease | contraindication | 302226006 | |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Smokes tobacco daily | contraindication | 449868002 | |
Protozoal Infection | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.29 | acidic |
pKa2 | 7.0 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
DNA | DNA | OTHER | CHEMBL | CHEMBL |
ID | Source |
---|---|
4019906 | VUID |
N0000147991 | NUI |
D00478 | KEGG_DRUG |
366-70-1 | SECONDARY_CAS_RN |
4017789 | VANDF |
4019906 | VANDF |
C0033223 | UMLSCUI |
CHEBI:71417 | CHEBI |
CHEMBL1321 | ChEMBL_ID |
CHEMBL1200410 | ChEMBL_ID |
D011344 | MESH_DESCRIPTOR_UI |
DB01168 | DRUGBANK_ID |
7278 | IUPHAR_LIGAND_ID |
2147 | INN_ID |
35S93Y190K | UNII |
4915 | PUBCHEM_CID |
66925 | RXNORM |
5360 | MMSL |
d00354 | MMSL |
002672 | NDDF |
004827 | NDDF |
10174003 | SNOMEDCT_US |
387474003 | SNOMEDCT_US |
81583003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Matulane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54482-054 | CAPSULE | 50 mg | ORAL | NDA | 23 sections |